Clinical Trial Update: Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PDE5 inhibitors for endocrine cardiomyopathy in Cushing syndrome; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome Cardiomyopathy

Drugs mentioned

• cyclic GMP PDE5 inhibitors (PDE5 inhibitor)

Snippet

Sponsor: Andrea M. Isidori | Conditions: Cushing's Syndrome Cardiomyopathy | Phase 2 | Status: COMPLETED